Atomo Diagnostics (ASX:AT1): Can Its Pascal Platform Expand Beyond HIV Testing?

Aditi Sarkar

13 November 2026 03:25 PM AEDT

Atomo Diagnostics (ASX:AT1): Can Its Pascal Platform Expand Beyond HIV Testing?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Atomo Diagnostics (ASX:AT1) reported FY26 Revenue of AUD 5.3 million.
Revenue rose 41% while the underlying EBITDA loss narrowed 39%.
Partner Supply revenue reached AUD 2.2 million in FY26.
The company ended June with AUD 3.7 million cash and no debt.

Atomo Diagnostics Limited (ASX:AT1) develops and supplies rapid diagnostic testing technology, including its own HIV tests and a device platform used by partner companies. On 13 November 2026, Atomo’s shares changed hands at AUD 0.013, up 4.17% during the session. Its FY26 results and subsequent strategy update provide the current context for the business, with attention on the Pascal platform, commercial testing channels and development of additional diagnostic applications.

Rapid Tests and the Pascal Partner Platform

Atomo operates two principal commercial models: selling finished diagnostic products under its own portfolio and supplying the Pascal platform for use in tests developed by partners. Its HIV self-test and professional-use offerings serve different distribution settings. Partner programmes extend the same device architecture into other diagnostic categories. The distinction matters because a partner’s test sales, the number of Pascal units ordered and the revenue recognised by Atomo are not automatically equal.

Rapid Tests and the Pascal Partner Platform

Atomo Diagnostics (ASX:AT1) identifies FebriDx, supplied through Lumos Diagnostics, as an application of its platform and points to partner activities involving ferritin and another test category. Its development pipeline includes active syphilis and liver-function testing. Each prospective assay requires its own validation, regulatory process and commercial execution. A platform already in use does not automatically confer approval for a new test or guarantee commercial ordering.

FY26 Growth and Commercial Milestones

Atomo reported FY26 revenue of AUD 5.3 million, an increase of 41%. Its HIV test revenue reached AUD 2.8 million, up 21%, while partner supply revenue on Pascal was AUD 2.2 million, up 209%. These figures illustrate that both commercial channels contributed to reported revenue growth, though their sales models are different. The company said its underlying EBITDA loss improved 39%, narrowing from AUD 3.38 million to AUD 2.06 million.

FY26 Growth and Commercial Milestones

The Business reported AUD 3.7 million in cash at 30 June 2026 and said it ended the financial year debt-free. Atomo also identifies an AUD 3 million Capital raising completed in April. Its investor update reports a US Food and Drug Administration CLIA Waiver for the FebriDx application on the Pascal platform in April, following a clearance pathway advanced by its partner Lumos. That waiver relates to the specified product and testing setting, not every test under development.

Product Pipeline and FY27 Sector Context

Atomo reported completion of technical development for active syphilis testing in June 2026 and targeted Clinical Trials from early calendar 2027. It also added an alanine aminotransferase liver-function test to its development pipeline. Its website describes a ferritin programme undergoing validation and registration, alongside a UK partner project that has reached a feasibility stage. These are different stages of progress and should not be counted as approved commercial products.

Product Pipeline and FY27 Sector Context

Atomo scheduled its September-quarter FY27 activities and Cash Flow disclosure for 30 October and a quarterly investor webinar for 3 November. The business discussed its commercial channels and pipeline as part of a September strategy update. Market Demand for decentralised diagnostics depends on reimbursement, procurement, clinical practice and test performance, while regulatory pathways vary across geographies. Reported partner Volume and recognised revenue will be useful to track against the FY26 baseline.

Risks and Operational Milestones

Risks include concentration in a limited number of commercial partners, delays in diagnostic validation, regulatory review and variability in orders from pharmacy and clinical customers. The underlying EBITDA measure remained a loss in FY26 despite improvement, making expenditure and cash conversion relevant. New test categories require evidence and operational resources before commercialisation can be assumed. Partner revenue is also dependent on partners’ distribution and procurement decisions.

What to Watch Next

Monitoring priorities include actual Pascal unit supply, the pace of HIV test distribution, progress on active syphilis clinical trials and any regulatory submissions for pipeline products. Further quarterly disclosures should show operating cash flows and whether the growth achieved in FY26 is sustained. The timing of new agreements and product registrations should be distinguished from subsequent shipment volumes and recognised revenue.

Key Insights

Atomo Diagnostics (ASX:AT1) increased FY26 revenue and reduced its underlying EBITDA loss, supported by HIV testing and Pascal partner supply. The company retains a development pipeline that has not yet reached the same commercial stage across all products. Cash movement, partner orders and regulatory milestones remain important indicators of execution.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.